Noxopharm Ltd has released a press release.
Appendix 4D and FY2026 Half Year Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- R&D rebate strengthens cash position
- At-the-Market (ATM) agreement with Acuity Capital
- Sofra breakthrough science publish in major medical journal
- December 2025 Quarterly Activities Report and Appendix 4C
- HERACLES clinical trial successfully completed
Later from Noxopharm
- Resignation of Chief Executive Officer
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Positive SOF-SKN dosing data shows prolonged skin retention
- March 2026 Quarterly Activities Report and Appendix 4C
- Innovative collaboration further expands Sofra platform
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm